In vivo Octreotide Administration Acutely Reduces Exocrine Granule Size in the Human Pancreas

Pancreatology

Volumn 1, Issue 1, 2001, Pages 30-35

  Falconi, Massimo ^a   Caldiron, Erminia ^a   Zancanaro, Carlo ^a   Benati, Donatella ^a   Talamini, Giorgio ^a   Bassi, Claudio ^a   Pederzoli, Paolo ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Complications; Electron microscopy; Exocrine gland; Morphometry; Somatostatin; Surgery

Indexed keywords

OCTREOTIDE;

ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; HISTOLOGY; HUMAN; MALE; MIDDLE AGED; PANCREAS; PANCREAS TUMOR; PATHOLOGY; REFERENCE VALUE; SECRETORY VESICLE; ULTRASTRUCTURE;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PANCREAS; PANCREATIC NEOPLASMS; REFERENCE VALUES; SECRETORY VESICLES;

EID: 0035553709     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000055789     Document Type: Article

References (36)

1. Trede M, Schwall G: The complications of pancreatectomy. Ann Surg 1988;207:39-47.
2. Crist DW, Sitzmann JV, Cameron JL: Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987;206:358-365.
3. Pellegrini CA, Heck CF, Raper S, et al: An analysis of the reduced morbidity and mortality after pancreaticoduodenectomy. Arch Surg 1989;124:778-781.
4. Kohler E, Beglinger C, Ribes G, et al: Effect of a new somatostatin analogue on pancreatic function in healthy volunteers. Pancreas 1986;1: 154-159.
5. Creutzfeldt W, Lembcke B, Folsch U, et al: Effects of somatostatin analogue (SMS 201-995) on pancreatic secretion in humans. Am J Med 1987;82(suppl 5b):49-54.
6. Lembcke B, Creutzfeldt W, Schleser S, et al: Effect of the somatostatin analogue (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 1987;36:108-124.
7. Arnold R, Lankisch PG: Somatostatin and the gastrointestinal tract. Clin Gastroenterol 1980; 9:73-53.
8. Von der Ohe M, Layer P, Wollny C, Ensink JW, et al: Somatostatin 28 and coupling of human interdigestive intestinal motility and pancreatic secretion. Gastroenterology 1992; 103:974-981.
9. Hildebrand P, Ensink JW, Gyr K, et al: Evidence for hormonal inhibition of exocrine pancreatic function by somatostatin 28 in humans. Gastroenterology 1992;103:240-247.
10. Patel YC: Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-198.
11. Guan D, Maouyo D, Sarfati P, Morriset J: Effects of SMS 210-995 on basal and stimulated pancreatic secretion in rats. Endocrinology 1990;127:298-304.
12. Konturek SJ, Bilski J, Jaworek J, et al: Comparison of somatostatin and its highly potent hexa-and octapeptide analogues on exocrine and endocrine pancreatic secretion. Proc Soc Exp Biol Med 1988;187:241-249.
13. Gullo L, Biliotti G, Pezzilli R, Di Stefano M, Ancona D: Effect of octreotide (SMS 201-995) on meal-stimulated pancreatic secretion in three patients with external pancreatic fistola. Am J Gastroenterol 1991;86:892-894.
14. Berberat PO, Friess H, Uhl W, et al: The role of octreotide in the prevention of complications following pancreatic resection. Digestion 1999; 60(suppl 2):15-22.
15. Barnes SM, Konty BG, Prinz RA: Somatostatin analog treatment of pancreatic fistulas. Int J Pancreatol 1993;14:181-188.
16. Bassi C, Falconi M, De Santis L, et al: Role of somatostatin and its analogues in gastrointestinal fistulas, ascites and pancreatic pseudocysts. Dig Surg 1994;11:451-455.
17. Benedetti E, Coady NT, Asolati M, et al: A prospective randomized clinical trial of perioperative treatment with octreotide in pancreas transplantation. Am J Surg 1998;175:14-17.
18. Buchler MW, Fiess H, Klempa I, et al: Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg 1992;163:125-131.
19. Pederzoli P, Bassi C, Falconi M, et al: Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Italian Study Group. Br J Surg 1994;81:265-269.
20. Lowy AM, Lee JE, Pisters PWT, et al: Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 1977;226: 632-641.
21. Gullo L, Pezzilli R, Barbara L: Effect of somatostatin on plasma aminoacid uptake by human pancreas. Gastroenterology 1989;97:732-736.
22. Matsushita K, Okabayashi Y, Hasegawa H, et al: In vitro inhibitory effect of somatostatin on secretin action in exocrine pancreas of the rat. Gastroenterology 1993;104:1146-1152.
23. Ohnishi H, Mine T, Kojima I: Inhibition by somatostatin of amylase secretion induced by calcium and cyclic AMP in rat pancreatic acini. Biochem J 1994;304:531-536.
24. Kohler E, Berlinger C, Dettwiler S, et al: Effect of a new somatostatin analogue on pancreatic function in healthy volunteers. Pancreas 1986; 2:154-159.
25. Harris AG: Octreotide in the treatment of disorders of the gastrointestinal tract. Drug Invest 1992;4(suppl 3):1-54.
26. Jamieson JD, Palade GE: Intracellular transport of secretory proteins in the pancreatic exocrine cell. III. Dissociation of intracellular transport from protein synthesis. J Cell Biol 1968;39:580-588.
27. Jenkins SA, Nott DM, Baxter JN: Fluctuations in the secretion of pancreatic enzymes between consecutive administrations of octrcotidc: Implications in the management of fistulac. Eur J Gastroenterol Hepatol 1995;7:255-280.
28. Sakamoto C, Golfine ID, Williams JA: The somatostatin receptor on isolated pancreatic acinar cell plasma membranes. Identification of subunit structure and direct regulation by cholecystokinin. J Biol Chem 1984;259:9623-9627.
29. Esteve JP, Susini C, Vaysse H, et al: Binding of somatostatin to pancreatic acinar cells. Am J Physiol 1984;247:G62-G69.
30. Hunyady B, Hipkin W, Schonbrunn A, et al: Immunohistochemical localization of somatostatin receptor SST2A in the rat pancreas. Endocrinology 1997;138:2632-2635.
31. Rossowski WJ, Gu ZF, Akarca US, et al: Characterization of somatostatin receptor subtypes controlling rat gastric acid and pancreatic amylasc release. Peptides 1994;15:1421-1424.
32. Hoyer D, Lübbert H, Bruns C: Molecular pharmacology of somatostatin receptors. Naunyn Schmiedebergs Arch Pharmacol 1994;350: 441-453.
33. Reisine T, Bell GI: Molecular biology of somatostatin receptors. Endocr Rev 1995;16:427-442.
34. Heisler S, Srikant CB: Somatostatin-14 and somatostatin-28 pretreatment down-regulate somatostatin-14 receptors and have biphasic effect on forskolin-stimulated cyclic adenosine, 3′,5′-monophosphate synthesis and adrenocorticotropin secretion in mouse anterior pituitary tumor cells. Endocrinology 1985;117:217-225.
35. Londong W, Angerer M, Kutz K, et al: Diminishing efficacy of octreotide (SMS 201-995) on gastric function of healthy subjects during one-week administration. Gastroenterology 1989; 96:713-722.
36. Li Y, Owyang C: Somatostatin inhibits pancreatic enzyme secretion at a central vagal site. Am J Physiol 1993;265:G251-G257.